GLP-1 & metabolic / Investigational combination

CagriSema: cagrilintide with semaglutide, from the phase 3 studies

CagriSema is the name used in the studies for cagrilintide, an amylin analogue, given together with semaglutide, a GLP-1 receptor agonist. It is not FDA-approved: Drugs@FDA lists no product containing cagrilintide (checked 19 November 2026). It was tested in the two 2025 phase 3 studies described below. PinPoint keeps the two as separate compounds, each with its own page and record, and this page follows the same rule.

Editorial still life from the PinPoint compound library series

ILLUSTRATION / COMPOUND LIBRARY SERIES

What is CagriSema, and what does the search ask?

The two phase 3 papers describe CagriSema as the coadministration of cagrilintide and semaglutide, the combination studied for weight management [3][4]. Cagrilintide is a long-acting amylin analogue [5]; no FDA-approved medicine contains it [2]. Semaglutide is FDA approved and has its own labels [1]. REDEFINE 1 also had arms with semaglutide alone and cagrilintide alone; its main comparison was the combination against placebo [3].

People searching the name want to know what it is, how it compared with semaglutide alone, and what amounts were studied. The first two have published answers. The third is left to the papers themselves: their study assignments describe research populations, and this page does not restate them as a schedule for anyone.

What do the CagriSema phase 3 studies report?

REDEFINE 1, published in 2025, was a 68-week, double-blind phase 3a study of 3417 adults without diabetes who had obesity, or overweight with a related condition [3]. Participants were randomly assigned to the combination, to semaglutide alone, to cagrilintide alone, or to placebo, each with lifestyle support. Mean body-weight change at 68 weeks was 20.4% lower with the combination and 3.0% lower with placebo. Gastrointestinal adverse events affected 79.6% of the combination group and 39.9% of the placebo group, mostly mild to moderate and transient.

REDEFINE 2, published alongside it, enrolled 1206 adults with type 2 diabetes, a body-mass index of 27 or more and a glycated haemoglobin of 7 to 10%, assigned 3 to 1 to the combination or placebo for 68 weeks [4]. Mean weight change was 13.7% lower against 3.4% lower, and 73.5% of the combination group reached a glycated haemoglobin of 6.5% or less, against 15.9% on placebo. Gastrointestinal adverse events were reported by 72.5% of the combination group and 34.4% of the placebo group, most transient and mild or moderate.

An earlier 2021 phase 1b study measured cagrilintide pharmacokinetics alongside semaglutide and reported a cagrilintide half-life of 159 to 195 hours [5]. The figure in this section shows reported group means from the two phase 3 papers; they describe study populations and are not an expected outcome for any one person.

From each compound page
CompoundStatusHalf-life
CagrilintideInvestigational. No FDA-approved medicine contains cagrilintide (Drugs@FDA, checked 19 November 2026).159 to 195 hours, measured for cagrilintide given once weekly with semaglutide 2.4 mg in the cited study.
SemaglutideSemaglutide is an FDA-approved prescription medicine (first US approval 2017); the cited label is for a once-weekly injection for adults with type 2 diabetes.Approximately 1 week (elimination half-life); semaglutide is present in the circulation for about 5 weeks after the last dose, per the label.
Mean percent body-weight change at 68 weeks by study group, as reportedCagriSema, R1: 20.4 percent lower; Placebo, R1: 3 percent lower; CagriSema, R2: 13.7 percent lower; Placebo, R2: 3.4 percent lower. Group means from two published phase 3 studies, not individual expectations. MEAN PERCENT BODY-WEIGHT CHANGE AT 68 WEEKS BY STUDY GROUP, AS REPORTED CagriSema, R1−20.4%Placebo, R1−3%CagriSema, R2−13.7%Placebo, R2−3.4%
Reported group means from a published study. Not an expected individual outcome.

How is CagriSema measured and converted?

No source on this page describes a CagriSema presentation to convert, so there is no stated combined pen, no concentration and no syringe-unit figure, and this page does not build one by adding two amounts together [3]. Each component is measured on its own, from its own product.

The phase 1b study measured a cagrilintide half-life of 159 to 195 hours [5], and the semaglutide label gives an elimination half-life of approximately 1 week [1]. The website's cagrilintide calculator and semaglutide calculator each work from the amount and volume entered for one product; the two are never mixed into one figure.

CagriSema: no presentation cited here for a units conversion
Cagrilintide: 159 to 195 hours measured with semaglutide (phase 1b)
Semaglutide: approximately 1 week, per its label

How do people log cagrilintide and semaglutide in PinPoint?

Both compounds are in PinPoint's library, so each is logged as its own entry with compound, dose, site and pain level [6]. Each record keeps its own schedule, set by the user, with reminders tied to the day and time set [6].

The Home curve is a model drawn from the app's inputs; for cagrilintide they are estimates, not measured averages, and it does not account for individual variation [6]. Weight, side effects with severity ratings and daily notes can be recorded beside both, and prefilled pens and vials are tracked side by side [6].

Get PinPoint on the App Store

What do people ask about CagriSema?

What is CagriSema?
CagriSema is the name used in the studies for cagrilintide, an amylin analogue, given with semaglutide, a GLP-1 receptor agonist. Drugs@FDA lists no product containing cagrilintide (checked 19 November 2026).
How much weight did people lose on CagriSema in phase 3?
In REDEFINE 1, mean body weight was 20.4% lower at 68 weeks against 3.0% on placebo. In REDEFINE 2, in adults with type 2 diabetes, it was 13.7% against 3.4%. Gastrointestinal adverse events were reported by 79.6% and 72.5% of the combination groups, against 39.9% and 34.4% on placebo.
Is CagriSema FDA approved?
No. Drugs@FDA lists no product containing cagrilintide (checked 19 November 2026). The 2025 phase 3 papers studied it as an investigational combination. Semaglutide alone has FDA labels, covered on its own page.
Can CagriSema be tracked in one app?
PinPoint records cagrilintide and semaglutide as two separate compounds with separate schedules and curves. PinPoint is a tracking app, and its modeled curves do not account for individual variation.

Where do these facts come from?

Sources are listed by kind: labels and regulators first, then peer-reviewed papers, then the app description. Arithmetic is worked from the inputs stated beside it and is not a source; an example vial size is an arithmetic input, not a sourced fact.

  1. Semaglutide injection prescribing information (DailyMed)DailyMed SPL of 1 June 2026. Elimination half-life of approximately 1 week (section 12.3).Retrieved 2026-11-19 · label
  2. Drugs@FDA (openFDA), search for cagrilintideNo matches found (dataset last updated 18 November 2026).Retrieved 2026-11-19 · regulator
  3. Coadministered cagrilintide and semaglutide in adults with overweight or obesity, 2025New England Journal of Medicine, 2025 (REDEFINE 1). Phase 3a, 68 weeks, 3417 participants; combination, each component alone, or placebo.Retrieved 2026-10-05 · study
  4. Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes, 2025New England Journal of Medicine, 2025 (REDEFINE 2). Phase 3a, 68 weeks, 1206 participants, 3:1 to combination or placebo.Retrieved 2026-10-05 · study
  5. Cagrilintide with semaglutide 2.4 mg, phase 1b study, 2021The Lancet, 2021. Ascending-dose study of cagrilintide with semaglutide over 20 weeks; pharmacokinetics including cagrilintide half-life of 159 to 195 hours.Retrieved 2026-10-05 · study
  6. PinPoint App Store descriptionFeature wording from the approved application description, not pricing.Retrieved 2026-10-05 · app-description